Amir Heshmatpour Purchases 9,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour purchased 9,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were purchased at an average price of $5.54 per share, with a total value of $49,860.00. Following the completion of the transaction, the chief executive officer owned 3,096,000 shares of the company’s stock, valued at approximately $17,151,840. This trade represents a 0.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Neonc Technologies Trading Up 16.5%

Shares of NASDAQ NTHI traded up $0.81 during trading on Tuesday, reaching $5.72. The stock had a trading volume of 253,076 shares, compared to its average volume of 93,199. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.01 and a fifty-two week high of $12.99. The business’s 50-day moving average price is $4.11 and its 200-day moving average price is $6.05.

Neonc Technologies (NASDAQ:NTHI) last posted its earnings results on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Institutional Investors Weigh In On Neonc Technologies

Large investors have recently bought and sold shares of the stock. HighPoint Advisor Group LLC increased its position in shares of Neonc Technologies by 20.5% during the fourth quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock worth $9,466,000 after purchasing an additional 194,408 shares in the last quarter. Bank of America Corp DE raised its stake in Neonc Technologies by 5.0% during the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock valued at $1,650,000 after acquiring an additional 11,108 shares during the last quarter. Westmount Partners LLC lifted its position in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the period. BlackRock Inc. acquired a new stake in Neonc Technologies during the 2nd quarter worth approximately $815,000. Finally, Vanguard Group Inc. purchased a new position in shares of Neonc Technologies in the 3rd quarter valued at approximately $1,279,000.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, May 26th. Maxim Group started coverage on shares of Neonc Technologies in a report on Monday, May 18th. They issued a “buy” rating and a $20.00 price objective for the company. Wall Street Zen downgraded shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings lowered shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 24th. Finally, Alliance Global Partners started coverage on shares of Neonc Technologies in a report on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $16.00.

Neonc Technologies News Roundup

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: NeOnc reported that a Phase 2a study of NEO100 in patients with recurrent IDH1-mutant high-grade glioma met its endpoint and extended survival. The results strengthen the company’s clinical narrative and could improve confidence in its CNS drug-development platform, although the program remains early-stage and still faces additional clinical and regulatory hurdles. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
• Positive Sentiment: CEO Amir Heshmatpour bought 12,000 shares on August 14 at approximately $3.79 each and another 3,000 shares on August 17 at approximately $4.37 each, investing roughly $58,600 in total. The purchases increased his already substantial ownership to about 3.087 million shares and may be viewed as a signal of management confidence. NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
• Neutral Sentiment: Analyst coverage remains broadly constructive, with several Buy ratings and price targets well above recent trading levels, but the overall consensus is Hold because at least one analyst has issued a Sell rating. Reported purchases by several institutional investors also provide some support, though they do not eliminate the company’s clinical and financing risks.
• Negative Sentiment: Stockholders approved expanding the company’s equity plan by 1 million shares. The additional authorization could help fund operations and development, but it also creates potential dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve 1M-Share Equity Plan Expansion
• Negative Sentiment: NeOnc reported a quarterly loss of $0.58 per share, substantially worse than the $0.12 loss analysts expected. The result highlights the company’s lack of near-term profitability and ongoing need for capital while it advances NEO100.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.